Showing 19 of 19 recruiting trials for “Non-Hodgkin lymphoma”
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
RecruitingNCT07313943 ↗
PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGE
Amping up With PemJAK
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
👨⚕️ Christina Dieli-Conwright, MD, PhD, Dana-Farber Cancer Institute📍 1 site📅 Started Jun 2025View details ↗
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
👨⚕️ Randall Michael, MD, University of California, San Francisco📍 1 site📅 Started Oct 2024View details ↗
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
👨⚕️ Jelle Kijlstra, MD, MBA, BobcatBio, p/k/a SIRPant Immunotherapeutics📍 3 sites📅 Started Jan 2024View details ↗
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
👨⚕️ Indapta Therapeutics, Inc., Indapta Therapeutics, INC.📍 12 sites📅 Started Oct 2023View details ↗
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
Improving Exercise Capacity With a Tailored Physical Activity Intervention
👨⚕️ William Hundley, MD, Wake Forest Baptist Comprehensive Cancer Center📍 2 sites📅 Started Mar 2023View details ↗
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
👨⚕️ Junyuan Qi, MD, PHD, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences📍 4 sites📅 Started Nov 2021View details ↗
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Auto Stem Cell Transplant for Lymphoma Patients
👨⚕️ Veronika Bachanova, MD, Masonic Cancer Center, University of Minnesota📍 1 site📅 Started Apr 2017View details ↗
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →